Nothing Special   »   [go: up one dir, main page]

RU2016148710A - Agent for treating a disease accompanied by macular edema due to increased expression of VEGF-A - Google Patents

Agent for treating a disease accompanied by macular edema due to increased expression of VEGF-A Download PDF

Info

Publication number
RU2016148710A
RU2016148710A RU2016148710A RU2016148710A RU2016148710A RU 2016148710 A RU2016148710 A RU 2016148710A RU 2016148710 A RU2016148710 A RU 2016148710A RU 2016148710 A RU2016148710 A RU 2016148710A RU 2016148710 A RU2016148710 A RU 2016148710A
Authority
RU
Russia
Prior art keywords
vegf
increased expression
macular edema
treating
agent
Prior art date
Application number
RU2016148710A
Other languages
Russian (ru)
Other versions
RU2669787C2 (en
RU2016148710A3 (en
Inventor
Александр Михайлович ШУСТЕР
Равиль Авгатович Хамитов
Светлана Георгиевна Аббасова
Игорь Павлович Фабричный
Дмитрий Александрович Потеряев
Вероника Николаевна Бадэ
Original Assignee
Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" filed Critical Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум"
Priority to RU2016148710A priority Critical patent/RU2669787C2/en
Priority to PCT/RU2017/050121 priority patent/WO2018111156A1/en
Publication of RU2016148710A publication Critical patent/RU2016148710A/en
Publication of RU2016148710A3 publication Critical patent/RU2016148710A3/ru
Application granted granted Critical
Publication of RU2669787C2 publication Critical patent/RU2669787C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Claims (3)

1. Полипептид, содержащий F(ab')2 терапевтического антитела, для введения в стекловидное тело для целей лечения и/или профилактики заболевания, в отношении которого указанное антитело имеет терапевтическую активность.1. The polypeptide containing F (ab ') 2 therapeutic antibodies, for introduction into the vitreous body for the treatment and / or prevention of a disease in respect of which the antibody has therapeutic activity. 2. Полипептид по п. 1, отличающийся тем, что указанное терапевтическое антитело представляет собой ранибизумаб, а указанное заболевание является заболеванием, сопровождающимся отеком макулы вследствие повышенной экспрессии VEGF-A.2. The polypeptide according to claim 1, characterized in that said therapeutic antibody is ranibizumab, and said disease is a disease accompanied by macular edema due to increased expression of VEGF-A. 3. Полипептид по п. 1, отличающийся тем, что дополнительно содержит полипептидные последовательности, выбранные из домена СН3 антитела, неструктурированных полипептидов, в том числе, НАР-полипептидных последовательностей S(G4S)16 и S(G4S)20, или их комбинации.3. The polypeptide according to claim 1, characterized in that it further comprises polypeptide sequences selected from the CH3 domain of an antibody, unstructured polypeptides, including HAP polypeptide sequences S (G 4 S) 16 and S (G 4 S) 20 , or combinations thereof.
RU2016148710A 2016-12-13 2016-12-13 Means for treatment of disease with macular oedema due to excessive vegf-a expression RU2669787C2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
RU2016148710A RU2669787C2 (en) 2016-12-13 2016-12-13 Means for treatment of disease with macular oedema due to excessive vegf-a expression
PCT/RU2017/050121 WO2018111156A1 (en) 2016-12-13 2017-12-07 A drug for treating diseases correlated with macular oedema associated with vegf-a overexpression

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2016148710A RU2669787C2 (en) 2016-12-13 2016-12-13 Means for treatment of disease with macular oedema due to excessive vegf-a expression

Publications (3)

Publication Number Publication Date
RU2016148710A true RU2016148710A (en) 2018-06-13
RU2016148710A3 RU2016148710A3 (en) 2018-06-13
RU2669787C2 RU2669787C2 (en) 2018-10-16

Family

ID=62559578

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016148710A RU2669787C2 (en) 2016-12-13 2016-12-13 Means for treatment of disease with macular oedema due to excessive vegf-a expression

Country Status (2)

Country Link
RU (1) RU2669787C2 (en)
WO (1) WO2018111156A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2761339C1 (en) * 2021-03-09 2021-12-07 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) Method for determining the expression level of the gene encoding vegf-a in the eye tissues of the oryctolagus cuniculus rabbit, and a kit for its determination

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903196A1 (en) * 2003-08-27 2005-03-10 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
RU2366388C1 (en) * 2008-04-29 2009-09-10 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Surgery technique for subretinal haemorrhages combined with age-specific macular dystrophy with subretinal neovascular membrane
MX2011002418A (en) * 2008-09-10 2011-04-05 Genentech Inc Methods for inhibiting ocular angiogenesis.

Also Published As

Publication number Publication date
RU2669787C2 (en) 2018-10-16
WO2018111156A1 (en) 2018-06-21
RU2016148710A3 (en) 2018-06-13

Similar Documents

Publication Publication Date Title
EA201890874A1 (en) ANTIBODIES THAT EFFECTIVELY NEUTRALIZE THE HEPATITIS B VIRUS AND THEIR USE
EA201890145A1 (en) ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION
EA201992163A1 (en) ANTIBODIES TO N3pGlu BETA AMYLOID PEPTIDE AND THEIR APPLICATION
BR112019008010A2 (en) isolated monoclonal antibody or immunologically active fragment thereof, isolated bispecific monoclonal antibody, pharmaceutical composition, method for treating a disease in a human subject in need thereof, fusion protein, cd47 gene encoded immunodominant epitope, and biological molecule
EA201891286A1 (en) ANTI-BETA AMYLOID PEPTIDE N3pGlu ANTIBODIES AND METHODS OF THEIR APPLICATION
EA201791168A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR EYE DISEASES
EA201891732A1 (en) BISPECIFIC BINDING PROTEINS FOR PD-L1 AND KDR
EA201790305A1 (en) COMBINED THERAPY OF AlZHEIMER'S DISEASE USING THE COMBINATION OF MONOCLONAL ANTIBODIES TO N3pGlu ABETA AND BACE INHIBITOR
EA201890725A1 (en) PHARNESIDE X-RECEPTOR AGONISTS AND THEIR APPLICATION
EA201790342A1 (en) ANTIBODIES TO TREM2 AND METHODS OF THEIR APPLICATION
NZ727024A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
EA201791590A1 (en) ANTIBODIES TO TAU AND THEIR APPLICATION
CY1124143T1 (en) BONE MORPHOGENETIC PROTEINS
EA201892225A1 (en) ANTIBODIES TO THE COMPLEX Bb FACTOR AND THEIR APPLICATION
EA201892541A1 (en) HUMANIZED ANTI-IL-1R3 ANTIBODIES
EA202190807A1 (en) ANTIBODIES TO SYNUCLEINE
MA47362A (en) ANTI-TNF ANTIBODIES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACTIVE PSORIASIC RHEUMATISM
WO2016061504A3 (en) Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein
EA201300130A1 (en) METHOD OF TREATMENT OF ALZHEIMER'S DISEASE
EA201892265A1 (en) METHODS OF TREATMENT OF OPHTHALMIC DISEASES
MX2019001958A (en) Methods of treating crohn's disease with an anti-nkg2d antibody.
EA202190094A1 (en) ANTIBODIES AGAINST CD40 FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASE
MA54132A (en) METHODS OF TREATING CROHN'S DISEASE WITH SPECIFIC ANTI-IL23 ANTIBODY
EA201590111A1 (en) MONOCLONAL HUMAN ANTIBODY AGAINST PROTECTION VP1 OF JC VIRUS
CO2020000260A2 (en) Chimeric antibodies for the treatment of amyloid deposition diseases

Legal Events

Date Code Title Description
PC43 Official registration of the transfer of the exclusive right without contract for inventions

Effective date: 20220228